Table 2 Clinical characteristics of participants at the end of follow-up
Clinical characteristics | |
|---|---|
Duration of follow-up (months, median [IQR]) | 35 (11) |
Serum creatinine (μmol/L, median [IQR]) | 78 (41) |
UPCR (g/g, median [IQR]) | 0.5 (1.0) |
eGFR (ml/min/1.73m2, mean [SD]) | 91.1 (34.7) |
ESRD (n [%]) | 16 (4.0) |
Endpoint event (n [%]) | 39 (9.8) |
Immunosuppressive therapy (n [%]) | 202 (50.1) |
ACEI/ARB (n [%]) | 255 (87.3) |